Cerus Corporation 2020 Form 10-K Summary
Business Context and Reporting Period
Cerus Corporation filed its annual report for the fiscal year ended December 31, 2020; the filing is not a quarterly report despite the request metadata referencing 2020 Q4. Cerus develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in donated blood components. Platelet and plasma systems were commercialized in the United States and selected international markets. The company received FDA approval in November 2020 for its cryoprecipitation system, which produces pathogen-reduced cryoprecipitated fibrinogen complex (PRCFC) and pathogen-reduced plasma, cryoprecipitate reduced. The red blood cell system remained in development.
Financial Performance and Key Metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Product revenue | $91.9 million | $74.6 million | Up 23% |
| Government contract revenue | $22.3 million | $19.1 million | Up 17% |
| Total revenue | $114.2 million | $93.8 million | Up 22% |
| Gross profit on product revenue | $50.8 million | $41.2 million | Up 23% |
| Product gross margin | 55% | 55% | Stable |
| Research and development expense | $64.4 million | $60.4 million | Up 7% |
| SG&A expense | $67.0 million | $66.2 million | Up 1% |
| Loss from operations | $(58.3) million | $(66.2) million | Improved |
| Net loss | $(59.9) million | $(71.2) million | Improved |
| Basic and diluted loss per share | $(0.37) | $(0.51) | Improved |
Total revenue increased primarily from higher disposable platelet kit sales in the United States and Europe and higher plasma kit sales in Europe and the Middle East. The company recorded a $0.3 million impairment charge related to machinery and equipment associated with a terminated agreement. Stock-based compensation increased to $18.0 million from $13.3 million.
Net cash used in operating activities was $40.7 million, compared with $65.8 million in 2019. Net cash used in investing activities was $49.6 million, primarily reflecting purchases of investments, while net cash provided by financing activities was $91.8 million. The company ended the year with $36.6 million of cash and cash equivalents, $97.0 million of short-term investments and $2.3 million of restricted cash. Working capital was $123.5 million.
Total debt was $48.1 million at year-end, consisting of $39.6 million of term debt and $8.5 million drawn under a revolving facility. The debt agreements mature in 2024, are secured by substantially all company assets subject to exclusions, and contain financial and other restrictive covenants. The company reported compliance with the covenants at December 31, 2020.
Material Changes Versus the Prior Comparable Period
- Product revenue increased 23%, with North American product revenue rising to $31.5 million from $20.6 million.
- Government contract revenue increased to $22.3 million from $19.1 million.
- Operating loss narrowed by approximately $7.9 million and net loss narrowed by approximately $11.4 million, aided by revenue growth and lower interest expense.
- Operating cash burn improved by approximately $25.1 million, partly because 2019 included a $6.2 million payment to Fresenius.
- Cash and short-term investments increased substantially following a January 2020 equity offering that generated approximately $62.7 million net, as well as additional equity proceeds.
- Total shares outstanding increased to approximately 168.2 million at year-end from 144.3 million at year-end 2019, reflecting equity offerings and equity awards.
- In April 2020, BARDA committed additional funding, bringing committed funding under the agreement to up to $116.9 million and potential total funding to $213.9 million through December 31, 2021, subject to options and milestones.
- In September 2020, Cerus entered into a five-year FDA agreement with potential contract value of $11.1 million for next-generation whole-blood pathogen-reduction compounds.
- In December 2020, Cerus established a new at-the-market equity program allowing sales of up to $100 million of common stock; no shares had been sold under that agreement by year-end.
Guidance, Outlook, Commentary, Risks and Unusual Items
Management expects product revenue to increase as U.S. adoption of INTERCEPT expands and commercialization progresses in other markets. A limited U.S. launch of PRCFC was expected to begin in 2021, with broader national commercialization expected in 2022. Management also expects selling, general and administrative expense to increase in 2021 and expects continued losses until widespread commercial adoption occurs, which may never happen.
The red blood cell program remains dependent on successful completion of the RedeS and ReCePI Phase 3 studies, additional studies, manufacturing validation and regulatory approvals. COVID-19 materially delayed enrollment and clinical activities. Cerus did not expect a red blood cell regulatory approval before 2022, if ever.
- COVID-19: The pandemic disrupted customer access, sales activity, clinical trial enrollment, hospital operations, supply-chain activities and potentially government funding. Further delays or renewed disruptions could reduce revenue and increase costs.
- BARDA dependency: Additional funding is discretionary, subject to milestones and government appropriations, and BARDA may terminate or modify the agreement for convenience. Failure to obtain extensions or additional funding could require Cerus to self-fund or discontinue portions of the red blood cell program.
- Commercial adoption: The company depends on adoption by a concentrated group of blood centers and hospitals. U.S. customers may choose other options under the FDA platelet safety guidance, particularly if Cerus cannot support required configurations, capacity or implementation timelines.
- PRCFC launch risk: Initial sales were expected to be limited to states where manufacturing partners are located until site-specific FDA biologics licenses are obtained. Cerus has limited experience selling finished biologic products directly to hospitals.
- Regulatory risk: Existing European products require transition to the Medical Device Regulation. Additional U.S. product configurations, post-approval studies and label expansions remain necessary for broader market access.
- Manufacturing concentration: Cerus relies on Fresenius and other sole or limited-source suppliers for disposable kits, compounds, adsorption components and illuminators. Component obsolescence, quality failures or supply interruptions could restrict sales and clinical development.
- Customer concentration: EFS represented 21% of 2020 product revenue and the American Red Cross represented 20%. EFS contracts have no purchase-volume commitments.
- Liquidity and financing: The company expects continuing cash needs and may require additional equity, debt, government funding or strategic financing. Further equity issuance would dilute shareholders.
- Other exposures: The company faces foreign-exchange risk, intellectual-property uncertainty, product-liability and recall risk, reimbursement uncertainty, cybersecurity risk and risks associated with restrictive debt covenants.
As a subsequent event, Cerus entered into a China joint venture in February 2021 with a Chinese company to develop, obtain approval for, manufacture and commercialize platelet and red blood cell versions of INTERCEPT in China. Cerus owns 51% of the joint venture.
Most Important Facts for Investors to Verify
- Whether U.S. adoption of platelet and plasma systems accelerates sufficiently to offset continued R&D and commercialization spending.
- The timing, geographic scope and economics of the PRCFC launch, including manufacturing-partner BLAs, reimbursement and hospital demand.
- Progress, safety findings and enrollment in the RedeS and ReCePI studies and the likelihood of red blood cell regulatory approval.
- The amount and timing of additional BARDA funding, contract extensions and any required company co-investment.
- Cash burn, debt repayment requirements, covenant compliance and the potential use of the $100 million at-the-market equity facility.
- Fresenius and other supplier capacity, component obsolescence, quality issues and the availability of qualified alternate suppliers.
- Revenue concentration and renewal or volume commitments from EFS, the American Red Cross and major distributors.
- Reapproval of INTERCEPT products under the European MDR and completion of required FDA post-approval studies.
- The impact of COVID-19 or subsequent public-health disruptions on customer implementation, clinical trials and supply continuity.